Danaher (DHR) Q3 Earnings Strengthen Confidence In Margin Expansion

Danaher entered this earnings day with the stock already on a steady climb, up about 21% over the past three months. Q3 2026 results added fuel, as the share price jumped another 4.3% to around $233 after the release. The headline story is profit power. Basic earnings per share reached about $1.71 on revenue of roughly $6.6b, while trailing 12 month net income from continuing operations came in near $4.3b. The market move suggests relief and renewed confidence, yet the real surprise is how firmly profitability is holding up.

Love the earnings resilience at Danaher but want a broader set of profitable compounders with sturdy balance sheets? Scan through the list of solid balance sheet and fundamentals stocks (25 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$6,554m vs. US$6,053m (up about 8.3%)
• Net Income from Continuing Operations, Trailing 12 Months (Q3 2026 vs. Q3 2025): US$4,289m vs. US$3,503m (up about 22.5%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$1.71 vs. US$1.28 (up about 34.3%)
• Net Profit Margin, Trailing 12 Months (Q3 2026 vs. Q3 2025): 16.7% vs. 14.4% (margin improved by about 2.3 percentage points)

Tired of squinting at dense earnings tables and scrolling through raw Danaher figures? Get the full story in a clean visual dashboard that lays out Danaher’s valuation profile in context through our company report for Danaher.

Danaher bullish thesis: recurring flywheel is gaining traction

Optimists argue that Danaher is building a higher quality, repeatable earnings engine around consumables and diagnostics rather than one off equipment swings.

"Analysts expect Danaher to continue compounding its mix of recurring consumables and diagnostics revenue, while converting earnings into strong free cash flow that supports buybacks and portfolio reshaping."

Q3 points in that direction. Core revenue ex respiratory grew 5.5% and Diagnostics ex respiratory delivered 7% core growth, helped by Cepheid and Beckman. Free cash flow reached US$1.6b in Q3 and US$4b year to date, which funded roughly US$900m of share repurchases in the first half and ongoing M&A, including Masimo and StatLab.

Danaher bear case: execution and China risks still live

Skeptics focus on whether end market friction, especially in bioprocessing and China, will blunt that recurring growth story.

"Volume based procurement and reimbursement changes in China that have already pressured Diagnostics revenue could extend beyond current expectations. Any further pricing pressure in that market would directly affect segment revenue and could compress net margins if not offset by cost efficiencies."

Q3 results ease some of that worry but do not erase it. Management flagged improving China dynamics for Beckman, which just logged its best core growth quarter in more than two years. At the same time, respiratory testing still created a 250 bps drag, and China pricing remains a watch item rather than a closed chapter.

The price and this Narrative do not agree. → Uncover what this Narrative says Danaher is actually worth.

Hunt For Mispriced Earnings Power

Danaher just showed how a single quarter can reset expectations around earnings resilience. The real opportunity is finding stocks that could be undervalued before the market reassesses their earnings power.

• Company 1 - 30% below our estimate - sells accelerated computing stacks that help cloud operators convert large AI backlogs into live capacity.
• Company 2 - 21% below our estimate - designs liquid cooling and power systems enabling high density AI racks to operate without relying on evaporative towers.
• Company 3 - 50% below our estimate - uses a dense store network and app-based ordering to convert increased urban foot traffic into recurring coffee transactions.

Those are three of them. See every one of the 33 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com